Project Grant R15GM167018
- The National Institute of General Medical Sciences awarded Worcester Polytechnic Institute $431,535 on August 10, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop and validate integrative machine learning methods for characterizing alternatively spliced isoforms of RNA-binding proteins and their functional roles in gene expression, RNA metabolism, and cellular homeostasis. The project will combine transcriptomic, proteomic, interactomic, and structural...
- The National Institute of General Medical Sciences awarded the University of Massachusetts Medical School $435,829 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support investigation of gut-brain communication mechanisms underlying behavioral state transitions. The research, led by the Alkema Lab, examines how internal states and environmental cues integrate to regulate behavior in C. elegans, using the organism's defined neural circuits, genetic...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Medical School $578,007 on August 1, 2026, for research on the gut-brain axis and microbial impact on neural function under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The project investigates mechanistic links between diet, gut microbiota, and neurological disorders including depression, migraine, anxiety, autism, schizophrenia, and...
- The National Institute of Neurological Disorders and Stroke awarded Worcester Polytechnic Institute $554,927 on June 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop and validate a reproducible blast-related traumatic brain injury model in the nematode C. elegans that enables controlled exposure to blast pressure waveforms with real-time measurement of neuronal activity and behavior in vivo. The research addresses...
- The National Institute of General Medical Sciences awarded Northeastern University $440,000 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to discover novel antimicrobial molecules from clostridial biosynthesis. The project characterizes cobalamin-dependent radical S-adenosylmethionine enzymes fused with non-ribosomal peptide synthetase adenylation domains found in clostridial genomes. The recipient will conduct biochemical characterization of these...
- The National Institute of General Medical Sciences awarded the University of Massachusetts $2.35 million on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate non-specific electrostatic interactions of biological macromolecules in physiological and pathological processes. The project examines how highly charged polycationic and polyanionic biomacromolecules — including heparin, neutrophil extracellular traps, and other polymeric species —...
- The National Institute of General Medical Sciences awarded the University of New Orleans $372,500 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, Assistance Type: Project Grant) to investigate the role of lipid metabolism in germline-soma interactions and stress responses using Caenorhabditis elegans as a model organism. The research examines how increased germline activity—specifically in mated hermaphrodite worms compared to self-fertilized...
- The National Institute of Neurological Disorders and Stroke awarded the President and Fellows of Harvard College $636,084 on May 12, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate structural, functional, and molecular remodeling of an adaptive sensorimotor circuit. The research uses C. elegans male mating behavior as a paradigm to understand experience-dependent plasticity across a sensorimotor circuit...
- The National Institute of General Medical Sciences awarded the University of Maryland Baltimore County $416,456 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support basic research into the genetic and endocrine regulation of multi-organ plasticity and sexually dimorphic behaviors. The research investigates how hormones coordinate physiological responses across multiple organ systems in response to environmental change, with particular focus on...
- The National Institute of General Medical Sciences awarded Massachusetts Institute of Technology $127,567 on September 3, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate mechanisms of nuclease-based bacterial immunity systems. The research, carried out in Cambridge, Massachusetts, through August 31, 2028, combines genetic and molecular biology approaches with training in biochemistry, structural biology, and computational methods to dissect how...
The National Institute of General Medical Sciences awarded Worcester Polytechnic Institute $554,599 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct research on how neuropeptides and monoamines establish sex-specific behavioral responses in the nematode Caenorhabditis elegans. The project will define the mechanisms by which NLP-3 neuropeptides and serotonin modulate a shared neural circuit to create sex-divergent avoidance behavior in response to the pheromone ascaroside-8, with applications to understanding sex differences in human neurological conditions including depression, Alzheimer's disease, autism, and schizophrenia. Work includes characterizing NLP-3-dependent modulation and receptor mechanisms of hermaphrodite avoidance and identifying serotonergic neurons and receptors that regulate this behavior through CRISPR genetics, calcium imaging, cell-specific neural manipulations, and peptide rescue experiments. Undergraduates and graduate trainees will lead behavioral assays and experimental work within a mentoring framework emphasizing rigor and reproducibility. Performance takes place in Worcester, Massachusetts, with a period of performance from August 1, 2026, through July 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $554.6k | 7/22/26 |